Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of iptacopan in C3 glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis
2023-509343-27-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 4, open-label trial of Iptacopan in Complement 3 glomerulopathy (C3G) and Primary immune complex membranoproliferative glomerulonephritis (MPGN) (2 arms), sponsored by Novartis. Planned start Oct 2019; status: authorised.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on 2023-509343-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509343-27-00.